HIGHLIGHTS
- who: ApoC-III and collaborators from the Department of Pediatrics, Section Molecular Genetics, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands have published the research: Clinical Medicine, in the Journal: (JOURNAL)
- what: In the meantime, the research community and the pharmaceutical industry are focusing on possibilities to further reduce risk by targeting other risk factors.
SUMMARY
2019, 8, 1085; 2 of 16 It also summarizes the latest information on the use of omega 3 fatty_acids (OM3FAs) to reduce ASCVD, compounds that not only affect TG but also inflammation (reviewed . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.